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Background. Herd immunity is important in the effectiveness of conjugate polysaccharide vaccines against
encapsulated bacteria. A large multicenter study investigated the effect of meningococcal serogroup C conjugate
vaccine introduction on the meningococcal population.
Methods. Carried meningococci in individuals aged 15–19 years attending education establishments were
investigated before and for 2 years after vaccine introduction. Isolates were characterized by multilocus sequence
typing, serogroup, and capsular region genotype and changes in phenotypes and genotypes assessed.
Results. A total of 8462 meningococci were isolated from 47 765 participants (17.7%). Serogroup prevalence
was similar over the 3 years, except for decreases of 80% for serogroup C and 40% for serogroup 29E. Clonal
complexes were associated with particular serogroups and their relative proportions fluctuated, with 12 statistically
significant changes (6 up, 6 down). The reduction of ST-11 complex serogroup C meningococci was probably due to
vaccine introduction. Reasons for a decrease in serogroup 29E ST-254 meningococci (from 1.8% to 0.7%) and an
increase in serogroup B ST-213 complex meningococci (from 6.7% to 10.6%) were less clear.
Conclusions. Natural fluctuations in carried meningococcal genotypes and phenotypes a can be affected by the
use of conjugate vaccines, and not all of these changes are anticipatable in advance of vaccine introduction.
The incorporation of protein-conjugate polysaccharide
vaccines into immunization schedules has been an im-
portant advance in the control of invasive bacterial
disease, especially meningitis. In 1992, Haemophilus
influenza serotype b conjugate (Hib) vaccine was the
first such vaccine introduced in the United Kingdom
(UK), followed by vaccines against Neisseria meningi-
tidis, the meningococcus, and Streptococcus pneumoniae
[1, 2]. In the case of meningococcal disease, still an
important cause of morbidity and mortality worldwide
[3], the deployment of meningococcal serogroup C
conjugate (MCC) vaccines in the UK in 1999 [4] sig-
nificantly reduced the incidence of serogroup C me-
ningococcal disease, providing impetus for the use of
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similar vaccines against other serogroups [5] (eg, the Meningitis
Vaccine Project serogroup A conjugate vaccine for sub-Saharan
Africa [6]).
In common with H. influenzae and S. pneumoniae, the
meningococcus is an accidental pathogen, normally colonizing
the human nasopharynx asymptomatically and rarely causing
invasive disease [7, 8], and the ability of the conjugate poly-
saccharide vaccines to generate herd immunity is important in
controlling the diseases they cause [2]. This is a consequence
of the vaccines inducing immunity in individuals across the
population that is not only long-lasting but also effective at
eliminating the carriage of capsulate bacteria, thereby inhibiting
their transmission. During the introduction of the MCC vaccines
in UK, the herd immunity effect was particularly strong [9, 10]
for 2 reasons. First, the vaccination campaign targeted all indi-
viduals ,18 years old [11] and later extended to those ,25 years
old, effectively immunizing the teenage age group among which
carriage was highest [11, 12]. Second, the ST-11 complex-
serogroup C meningococcal strain responsible for most serogroup
C disease in the UK at that time was particularly susceptible
to the effects of the vaccine, probably due to its high rate of
capsule expression [9]. This had the beneficial effect of ensuring
that the vaccine was effective, despite the suboptimal immu-
nization schedule initially used for infants (immunization at
2, 3, and 4 months of age with no booster at 1 year of age) [13],
because the outbreak strain was removed from asymptomatic
transmission [9].
Although populations of carried meningococci are genetically
and antigenically diverse, most disease is caused by a limited
number of genotype and serogroup combinations [8]. Of the 13
recognized meningococcal serogroups, 5 (A, B, C, Y, and W135)
are responsible for the majority of disease worldwide, with
meningococci that elaborate sialic acid–based capsules (sero-
groups B, C, Y, and W135) causing most disease in Europe,
North and South America, and Australasia [3]. The capsule is
encoded at the cps genome region [14], which may be occupied
by 1 of a number of possible gene clusters or a 115-bp inter-
genic region, the capsule null locus (cnl) [15]. Which of the
sialic acid–based capsules is synthesized depends on a single gene
within the cps which is referred to by various nomenclatures,
with the genes associated with the serogroups named as follows:
serogroup B, siaDB or synD; serogroup C, siaDC or synE; sero-
group W-135, siaDW or synF; and serogroup Y, siaDY or synG
[16–18]. The siaD nomenclature is used here to maintain con-
sistency with previous reports from this study [9].
Different serogroups and the cnl tend to be associated with
different genotypes, identified as clonal complexes by multilocus
sequence typing (MLST) [8, 19]. This includes the hyperinvasive
lineages, a subset of the many genotypes present in carried
meningococcal populations, which are responsible for most
invasive disease [8]. These associations are not absolute, how-
ever [20], which leads to the possibility that immunization
against asymptomatic carriage may generate a selective pres-
sure for the emergence of vaccine escape variants [17], which is
especially pertinent given the high rates of horizontal genetic
exchange seen in Neisseria [21]. Such variants arise from time
to time in meningococci, including changes between sero-
groups C and W-135 [17, 22, 23], but changes in response to
vaccination campaigns have yet to emerge as a major public
health threat.
Studies of the dynamics of carried meningococcal pop-
ulations and the effects of immunization on them play an in-
creasingly important part in the development of meningococcal
vaccines and assessing their effectiveness [24]. Here, changes in
predominant serogroups and genotypes of meningococci during
the course of MCC vaccine introduction in the UK are de-
scribed, and while the effect of the vaccine introduction on the
targeted serogroup has been reported elsewhere [9, 10, 12], to
our knowledge changes in the meningococcal population as
a whole are described here for the first time.
METHODS
Study Design and Samples
The study design has been described elsewhere [9, 10, 12].
Briefly, meningococcal carriage was surveyed in 15–19-year-old
students attending full-time education for 3 consecutive years in
7 centers throughout the UK, immediately before and 2 years
after the introduction of MCC vaccines (1999, 2000, and 2001).
Bacteria were isolated from nasopharyngeal swab samples. Each
participant completed a questionnaire on risk factors for car-
riage; formal records of the numbers of individuals approached
were not kept, but inspection of the school rolls indicated par-
ticipation rates were usually in.50% of those approached. The
demographic profile of those participating students matched
that of their schools.
Isolate Characterization
Isolates were phenotyped for species and serogroup using mi-
crobiological methods performed by the Health Protection
Agency (then Public Health Laboratory Service) Meningococcal
Reference Unit, for isolates from England and Wales, or the
Scottish Pneumococcal and Meningococcal Reference Labora-
tory (now the Scottish Haemophilus, Legionella, Meningococ-
cus and Pneumococcus Reference Laboratory) for isolates from
Scotland. A heat-killed cell suspension was prepared, as de-
scribed elsewhere [9], the multilocus sequence type was de-
termined, and the presence of siaD alleles and the cnl within the
cps region were detected by amplification with polymerase chain
reaction (PCR) for each isolate. The allele classes of the siaD
gene, siaDB (synD), siaDC (synE), siaDW (synF), and siaDY
(synG), were identified by sequencing of PCR products. Isolate
characteristics and questionnaire data were stored in a study-
specific database within the BIGSdb database platform [25].
Effects of Vaccination on Carried Meningococci d JID 2011:204 (1 October) d 1047
Assignment of Sequence Types to Clonal Complexes
Assignment of sequence types (STs) was performed automati-
cally by the BIGSdb software using a reference set of central
genotypes held within the database and approved by the Neis-
seria MLST Website management committee (http://pubmlst.
org/neisseria/info/). STs that were not assigned to a clonal
complex were examined by a combination of phylogenetic re-
construction with the neighbor joining algorithm using con-
catenated housekeeping gene sequences, split decomposition
analysis [26], and eBURST analysis [27] of the same data to
identify putative central genotypes of novel clonal complexes.
These were compared with data in the PubMLST Web site
[28], and where appropriate, new central genotypes were
proposed to, and subsequently approved by, the management
committee.
Data Manipulation and Analysis
Statistical analyses were performed using Intercooled Stata
software for Windows (version 10; Stata). Proportions were
compared using a v2 test or Fisher exact test as appropriate. Data
are presented for the 3 years of the study. The following com-
parisons over time were made: 1999 and 2000, 2000 and 2001,
and 1999 and 2001. There was a small degree of overlap between
individuals who were sampled on successive years, but for this
analysis each year was treated independently. Rate ratios and
confidence intervals were calculated comparing 2001 with 1999
to summarize change over time and are tabulated together with
the default (Woolf method) confidence intervals.
RESULTS
Sample Collection and Exclusion Criteria
From 1999 through 2000, 48 309 individuals were sampled across
the 7 study centers (Bangor, Cardiff, Glasgow, Nottingham,
Oxford, Plymouth, and Stockport). Of these, 47 765 (98.9%) met
the inclusion criteria of completing a questionnaire demon-
strating that they were in the correct age range (15–19 years
of age when sampled). A total of 9233 bacteria were isolated, of
which 8462 gave complete MLST profiles characteristic of me-
ningococci, a carriage rate of 17.7%. Carriage increased slightly
over the 3 years: it was 16.6% in 1999 (2306 isolates from 13 901
individuals), 17.6% in 2000 (2873 isolates from 16 295 in-
dividuals), and 18.7% in 2001 (3283 isolates from 17 569)
[9, 10]. The remaining 771 isolates (8.4% of isolates) comprised
bacteria that were phenotypically characterized as other species
(Neisseria lactamica, 324 isolates; Moraxella catarrhalis, 107 iso-
lates; other organisms or uncultivable at the reference laboratory,
210 isolates) and 130 isolates (1.4%) that were phenotypically
classified as meningococci but that had MLST profiles consistent
with N. lactamica. The data set differed slightly from that of the
8599 isolates reported elsewhere [9] as a consequence of using
a MLST-based, rather than phenotypic, approach to speciation
and by the exclusion of subjects on the basis of age calculated
from the questionnaire and sample dates.
Serogroups
Serogroup data were obtained for 8429 isolates (99.6%), with
3738 isolates (44%) grouped to 7 serogroups: B, C, 29E, W135, X,
Y, and Z. There were 4691 isolates (55.4%) that were not
groupable by the reagent panel used, and no data were available
for 33 isolates (0.4%). A single result was obtained for most
isolates, with 15 (0.2%) assigned as serogroup Z/29E. Over the
3 years, serogroup B organisms were the most common, ac-
counting for 2050 isolates (24.2%), and serogroup Z the least
common, with 36 isolates (0.4%). The proportion of serogroup
C meningococci decreased highly significantly over the study
period, from 2.7% to 0.5% of isolates (rate ratio for 2001 to
1999, 0.18; P , .001), as reported previously [9, 10], and the
proportion of serogroup 29E isolates decreased from 4.85% to
2.8% (rate ratio for 2001 to 1999, 0.58; P , .001). The pro-
portion of serogroup W135 isolates increased from 6.7% to 7.6%,
but this was statistically insignificant. There were only marginal
changes in the carriage proportion of other serogroups, none
statistically significant (Table 1).
Clonal Complexes
Five new clonal complexes were defined during this study:
ST-178 complex, ST-213 complex, ST-282, complex ST-1117
complex, and ST-1136 complex. Including these designations,
4290 isolates (88%) were assigned to 34 clonal complexes, and
572 isolates were not assigned. Carriage rates for clonal com-
plexes ranged from 13.7% (ST-41/44 complex; 1163 isolates) to
a single isolate (ST-37, ST-106, and ST-376 complexes) over the
whole study (Table 2). A number of temporal changes were
observed in the rates of carriage of clonal complexes: the pro-
portion of 6 decreased (the ST-11, ST-254, ST-865, ST-162,
ST-212, and ST-41/44 complexes), with rate ratios for 2001 to
1999 ranging from 0.20 (95% confidence interval [CI], .10–.37
[ST-11 complex]) to 0.86 (95% CI, .75–.98 [ST-41/44 com-
plex]), and the proportion of 6 increased (ST-213, ST-53,
ST-461, ST174, ST-269, and ST-1157 complexes), with rate ratios
for 2001 to 1999 ranging from 1.26 (95% CI, 1.06–1.50 [ST-53
complex]) to 3.98 (95% CI, 1.17–13.57 [ST-174 complex]). The
remaining clonal complexes showed no significant change over
the 3 years (14 clonal complexes) or were present in insufficient
numbers for changes to be assessed (8 clonal complexes). The
number of unassigned meningococci decreased from 9.3%
in 1999 to 6.8% in 2001. The statistically strongest effects
(P , .001) were the decreases in prevalence of the ST-11 com-
plex (rate ratio for 2001 to 1999, 0.20) and ST-254 complex (rate
ratio for 2001 to 1999, 0.38) and the increase in the proportion
of the ST-213 complex (rate ratio for 2001 to 1999, 1.60). Most
of the changes observed were consistent over the 3 years, with
the exceptions of a significant increase in the ST-1117 complex
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in 2000 relative to 1999 and a significant decrease in the ST-60
complex in the same year (Table 2).
Association of Serogroup and cps Genotype With Clonal
Complexes
For the 26 clonal complexes with .25 isolates, predominant
serogroup and cps genotypes were evident (Table 3). Fifteen
clonal complexes were associated with the sialic acid–containing
serogroups, 8 of which were mostly group B: ST-32 complex
(46% serogroup B, 86% siaDB), ST-35 complex (42% and 67%,
respectively), ST-41/44 complex (62% and 88%, respectively),
ST-162 complex (79% and 95%, respectively), ST-213 complex
(70% and 92%, respectively), ST-269 (50% and 74%, re-
spectively), ST-282 complex (79% and 98%, respectively), and
ST-461 complex (73% and 82%, respectively). Most of these
clonal complexes rarely exhibited other serogroups, but there
were 63 group C ST-41/44 complex isolates (1.5% serogroup C,
5.4% siaDC), 31 ST-35 complex group C isolates (3% serogroup
C and 11% siaDC), and 20 group C ST-269 complex isolates
(0.5% serogroup C, 5.5% siaDC). The ST-11 complex (58%
serogroup C, 89% siaDC) and ST-212 complex (4 % serogroup
C, 66% siaDC) were mostly group C, with the ST-22 complex
being mostly group W135 (54% serogroup W135, 85% siaDW).
Group Y was associated with 4 clonal complexes (ST-167
complex, ST-23 complex, ST-174 complex, and ST-92 complex);
1 complex was serogroup X (ST-103 complex) and 1 was se-
rogroup 29E (ST-60 complex). Four clonal complexes that
contained nongroupable isolates were associated with the cnl
(the ST-53, ST-198, ST-1117, and ST-1136 complexes). Three
clonal complexes (ST-178, ST-254, and ST-1157 complexes)
were not serogroupable and gave no result with the cps geno-
typing employed, indicating that they likely possessed capsules
and capsular regions not included in the serogroup and geno-
typing panel (Table 3).
Capsule Expression
For meningococci with a siaD gene, there was variation in
capsule expression by both serogroup and clonal complex. Ex-
pression rates of serogroup B capsule were 60%–100% for most
of the 11 clonal complexes with siaDB alleles, with the exceptions
of the ST-32 complex, with 76 (52%) of 146 isolates expressing
capsule, and the ST-865 complex, with 3 (13.5%) of 24 isolates
expressing capsule. There was statistically significant variation
(P 5 .002; Fisher exact test) in the rates of capsule expression
of the 5 clonal complexes associated with serogroup C, from
2 (10%) of 20 isolates for the ST-269 complex to 46 (64%) of
72 isolates for the ST-11 complex. One clonal complex (ST-22
complex) was associated with serogroup W135 and 576 (61%) of
these 945 isolates expressed this capsule. Rates of expression of
the serogroup Y capsule ranged from 56% (ST-167 complex) to
28% (ST-22 complex) (Table 4).
DISCUSSION
Herd immunity effects have made a major contribution to
the success of many vaccines, and they have been of particular
importance in vaccination with conjugate polysaccharide
vaccines against encapsulated bacteria [2]; indeed, for these
pathogens, the cost-effectiveness of immunization has been
substantially enhanced by this phenomenon [29]. For accidental
pathogens such as the meningococcus, inducing herd immunity
against a subset of the antigenic repertoire of the organism
potentially alters its niche, imposing selection pressure against
those variants that express the vaccine antigens during carriage
[21]. Given the complexity of the pharyngeal surface and its
microbiota [30], it is difficult to anticipate the likely effects of
this environmental change on the bacterial population, as the
elimination of a variant is likely to affect the prevalence of other
members of the microbiota.
Table 1. Carried Meningococcal Serogroups in the United Kingdom, 1999–2001
No. (%) of isolates
Serogroup
Year
Total
(n 5 8462)
Rate ratio, 2001 to 1999
(95% confidence interval) P
1999
(n 5 2306)
2000
(n 5 2873)
2001
(n 5 3283)
B 564 (24.5) 681 (23.7) 805 (24.5) 2050 (24.2) 0.99 (.91–1.09) .89
C 62 (2.7) 24 (0.8) 16 (0.5) 102 (1.2) 0.18 (.10–.31) ,.001
W135 155 (6.7) 234 (8.1) 251 (7.6) 640 (7.6) 1.13 (.93–1.37) .22
X 27 (1.2) 31 (1.1) 44 (1.3) 102 (1.2) 1.13 (.70–1.83) .61
Y 134 (5.8) 172 (6.0) 186 (5.7) 492 (5.8) 0.97 (.78–1.20) .75
Z 10 (0.4) 10 (0.3) 16 (0.5) 36 (0.4) 1.11 (.51–2.45) .79
Z/29E 3 (0.1) 7 (0.2) 5 (0.2) 15 (0.2) 1.16 (.28–4.85) .84
29E 111 (4.8) 98 (3.4) 92 (2.8) 301 (3.6) 0.58 (.44–.76) ,.001
Not groupable 1215 (52.7) 1613 (56.1) 1863 (56.7) 4691 (55.4) . .
No result 25 (1.1) 3 (0.1) 5 (0.2) 33 (0.4) . .
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Despite widespread horizontal genetic exchange among me-
ningococci, which can randomize genetic variation [31, 32],
meningococcal populations are dominated by clonal complexes,
which persist over time and during geographic spread [8, 33],
49 of which had been identified at the time of writing [8]. Iso-
lates from cases of disease mostly belong to one of the dozen or
so hyperinvasive lineages [3], with many more genotypes
observed in asymptomatic carriage than from invasive disease
[8, 20, 34]. Hyperinvasive meningococci are more likely to be
identified than those that are carried yet rarely cause disease and
it is likely that there are more noninvasive clonal complexes than
are currently recognized. For example, the 572 meningococci
unassigned to a clonal complex likely represented members of as
yet undefined clonal complexes that were present at low
Table 2. Meningococcal Clonal Complexes in the United Kingdom: Trends in Proportions of Carried Isolates, 1999–2001
No. (%) of isolates
Clonal complex
(multilocus sequence typing)
Year
Rate ratio, 2001 to 1999
(95% confidence interval) P
1999
(n 5 2306)
2000
(n 5 2873)
2001
(n 5 3283)
Total
(n 5 8,462)
Decrease over 3 years (P # .05)
ST-11 43 (1.9) 26 (0.9) 12 (0.4) 81 (1.0) 0.20 (.10–.37) ,.001
ST-865 20 (0.9) 18 (0.6) 10 (0.3) 48 (0.6) 0.35 (.16–.75) .005
ST-254 42 (1.8) 32 (1.1) 23 (0.7) 97 (1.1) 0.38 (.23–.64) ,.001
ST-162 28 (1.2) 29 (1.0) 19 (0.6) 76 (0.9) 0.48 (.27–.85) .01
ST-212 29 (1.3) 24 (0.8) 21 (0.6) 74 (0.9) 0.51 (.29–.89) .02
ST-41/44 349 (15.1) 389 (13.5) 425 (12.9) 1163 (13.7) 0.86 (.75–.98) .02
Increase over 3 years (P # .05)
ST-53 191 (8.3) 264 (9.2) 342 (10.4) 797 (9.4) 1.26 (1.06–1.50) .008
ST-1157 106 (4.6) 152 (5.3) 191 (5.8) 449 (5.3) 1.27 (1.00–1.60) .05
ST-269 88 (3.8) 114 (4.0) 165 (5.0) 367 (4.3) 1.32 (1.02–1.70) .03
ST-213 153 (6.6) 305 (10.6) 348 (10.6) 806 (9.5) 1.60 (1.33–1.92) ,.001
ST-461 6 (0.3) 12 (0.4) 26 (0.8) 44 (0.5) 3.04 (1.25–7.38) .01
ST-174 3 (0.1) 15 (0.5) 17 (0.5) 35 (0.4) 3.98 (1.17–13.57) .02
No change over 3 years (P . .05)
ST-22 272 (11.8) 407 (14.2) 430 (13.1) 1109 (13.1) 1.11 (.96–1.28) .15
ST-1117 35 (1.5) 85 (3.0) 66 (2.0) 186 (2.2) 1.32 (.88–1.99) .17
ST-198 87 (3.8) 109 (3.8) 148 (4.5) 344 (4.1) 1.19 (.92–1.55) .18
ST-23 91 (3.9) 106 (3.7) 154 (4.7) 351 (4.1) 1.19 (.92–1.53) .18
ST-167 121 (5.2) 155 (5.4) 147 (4.5) 423 (5.0) 0.85 (.67–1.08) .19
ST-92 9 (0.4) 10 (0.3) 7 (0.2) 26 (0.3) 0.55 (.20–1.46) .23
ST-178 32 (1.4) 32 (1.1) 34 (1.0) 98 (1.2) 0.75 (.46–1.21) .23
ST-750 44 (1.9) 49 (1.7) 49 (1.5) 142 (1.7) 0.78 (.52–1.17) .23
ST-32 54 (2.3) 49 (1.7) 66 (2.0) 169 (2.0) 0.86 (.60–1.23) .40
ST-1136 21 (0.9) 32 (1.1) 24 (0.7) 77 (0.9) 0.80 (.45–1.44) .46
ST-103 37 (1.6) 46 (1.6) 61 (1.9) 144 (1.7) 1.16 (.77–1.74) .48
ST-35 71 (3.1) 92 (3.2) 112 (3.4) 275 (3.2) 1.11 (.83–1.48) .49
ST-282 16 (0.7) 17 (0.6) 24 (0.7) 57 (0.7) 1.05 (.56–1.98) .87
ST-60 124 (5.4) 115 (4.0) 174 (5.3) 413 (4.9) 0.99 (.79–1.23) .90
Low-prevalence complexes
ST-8 7 (0.3) 1 (0.0) 4 (0.1) 12 (0.1)
ST-18 5 (0.2) 2 (0.1) 3 (0.1) 10 (0.1)
ST-364 3 (0.1) 2 (0.1) 3 (0.1) 8 (0.1)
ST-116 1 (0.0) 3 (0.1) 0 (0.0) 4 (0.0)
ST-334 2 (0.1) 0 (0.0) 0 (0.0) 2 (0.0)
ST-106 0 (0.0) 0 (0.0) 1 (0.0) 1 (0.0)
ST-376 1 (0.0) 0 (0.0) 0 (0.0) 1 (0.0)
ST-37 0 (0.0) 0 (0.0) 1 (0.0) 1 (0.0)
Unassigned isolates 215 (9.3) 181 (6.3) 176 (5.4) 572 (6.8)
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prevalence in the UK at the time of samplingda view that is
supported by the observation that 8 previously described clonal
complexes were represented by #12 isolates in this study.
Almost all meningococci that cause disease elaborate one of
the disease-associated capsules with hyperinvasive lineages that
tend to be associated with a particular serogroup, although the
precise association varies with time and place [20]. Although
possession of a capsule is normally necessary for virulence, it is
not in itself sufficient, because certain clonal complexes are as-
sociated with these capsules yet rarely or never invade [20].
Other clonal complexes are associated with the cnl genotype, and
these meningococci can be considered nonvirulent, yet they can
acquire capsules and cause disease. For example, the ST-53
complex is typically cnl and thought to be noninvasive, but the
first ST-53 meningococcus identified was a serogroup C clinical
isolate from the UK [35]: only 2 of the 797 ST-53 complex
meningococci isolated here possessed the siaDC gene. Non-
disease serogroups are also associated with clonal complexes,
showing that this phenomenon is not limited to invasive me-
ningococci. Consistent with disease patterns in the UK [36], no
serogroup A meningococci were isolated: the reasons for the
disappearance of this serogroup from transmission in the UK
since the 1970s [37] despite reintroduction [38] remain to be
explained, highlighting the dynamic nature of meningococcal
carriage and therefore disease prevalence, which alters over time
for reasons that remain poorly understood.
The UK’s implementation of the MCC vaccines was promp-
ted by the increased incidence of serogroup C meningococcal
disease, due to the global spread of serogroup C ST-11 me-
ningococcci [39]. The strain responsible (C: P1.5,2: ST-11 (cc11)),
identified as ET-15 by multilocus enzyme electrophoresis), was
first identified in Canada in 1986 and spread widely in North
America, Europe, Israel, and Australia during the 1990s [39, 40].
The MCC vaccines were very effective against this strain in the
UK and other countries by herd immunity effects [9]; however,
despite the potentially strong selective pressure imposed by
vaccine introduction, and the report of possible serogroup re-
placement in Spain [41], ST-11 complex meningococci ex-
pressing different serogroup variants of the ST-11 complex did
not spread in the UK during or immediately after the vaccine
introduction. Indeed, although serogroup W135 ST-11 complex
meningococci were introduced into the UK by Hajj pilgrims
[42] and increased in the postvaccination period, they did not
replace the serogroup C ST-11 clonal complex meningococci as
a major cause of disease in the UK [36].
Although the 80% reduction in carriage of serogroup C me-
ningococci was attributable to the vaccine introduction, the
reason for the 40% reduction in serogroup 29E carriage, with
a similar level of statistical significance (Table 1), was less ob-
vious. No other serogroup changed significantly over this time
period, although there were increases in serogroups W135, X, Y,
and Z. Although a causal link between vaccine introduction
and the reduction in serogroup 29E was not established, the
year-on-year reduction, similar to that seen for serogroup C,
Table 4. Expression of Serogroup by Different siaD Associated
Clonal Complexes
Group, siaD:cc
combinationa
Serogroup
positive
Genotype
positive
Percentage of isolates
expressing serogroup
B
siaDB:ST-18 10 10 100.0
siaDB:ST-461 31 36 86.1
siaDB:ST-162 58 72 80. 6
siaDB:ST-282 45 56 80.4
siaDB:ST-213 542 740 73.2
siaDB:ST-41/44 714 1023 69.8
siaDB:ST-1157 9 13 69.2
siaDB:ST-269 178 272 65.4
siaDB:ST-35 115 192 59.9
siaDB:ST-32 76 146 52.1
siaDB:ST-865 3 24 12.5
C
siaDC:ST-11 46 72 63.9
siaDC:ST-8 6 10 60.0
siaDC:ST-41/44 15 63 23.8
siaDC:ST-213 2 15 13.3
siaDC:ST-269 2 20 10.0
W135
siaDW:ST-22 576 945 61.0
Y
siaDY:ST-174 21 27 77. 8
siaDY:ST-167 190 339 56.1
siaDY:ST-92 12 23 52.2
siaDY:ST-23 128 319 40.1
siaDY:ST-22 19 67 28.4
a siaDB is equivalent to synD, siaDC to synE, siaDW to synF, and siaDY to
synG.
Table 3. Predominant Serogroups and cps Genotypes of the 26
Most Prevalent Carried Meningococcal Clonal Complexes
Isolated in the United Kingdom, 1999–2001
Serogroupa cps Genotypeb Clonal complex or complexes
B siaDB ST-32, ST-35, ST-41/44, ST-162,
ST-213, ST-269, ST-282, ST-461
C siaDC ST-11, ST-212
Y siaDY ST-23, ST-92, ST-167, ST-174
W135 siaDW ST-22
29E No result ST-60, ST-254
X No result ST-750
Z No result ST-103
Not groupable cnl ST-53, ST-198, ST-1117, ST-1136
Not groupable No result ST-178, ST-254, ST-1157
a Serogroup was detected immunochemically.
b The genotyping test detected only the siaD alleles or the capsule null
locus (cnl ): siaDB is equivalent to synD, siaDC to synE, siaDW to synF, and siaDY
to synG.
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was consistent with a vaccine effect. This is very unlikely to be
due to serological cross-reactivity between the structurally dis-
tinct serogroup 29E (3-deoxy-D-manno-octulosonic) [43] and
serogroup C (sialic acid) polysaccharides, although immuno-
logical cross-reactivity of the chemically related 29E and Z
capsules is known [44] and was seen in this study. A serogroup
29E isolate with a siaDC capsule gene has been reported [45],
but none of the 29E isolates examined exhibited this unusual
genotype. Thus, the reduction in carriage of serogroup 29E
(mostly ST-254 complex) meningococci may be a consequence
of a secondary interaction of meningococcal genotypes or an
unrelated change in carriage prevalence.
The other noteworthy change in the carried meningococcal
population over this time was the increase in the prevalence of
serogroup B ST-213 organisms. This clonal complex was absent
from 325 meningococcal isolates obtained from invasive disease
in England and Wales sampled from 1975 through 1995 [37], but
there was a sustained increase of this complex among disease
isolates in England and Wales after 1999 [46]. In the Impact of
Meningococcal Epidemiology and Population Biology on Public
Health in Europe (EU-MenNet) study, which analyzed .4000
representative disease isolates from throughout Europe from
2000 through 2002, the ST-213 clonal complex was present in the
UK (vaccine introduced in 1999), Ireland (2000), the Netherlands
(2002), and Denmark (vaccine not introduced), but not in other
European countries [47]. Furthermore, although the PubMLST
database (http://pubmlst.org/neisseria) is not a representative
epidemiological sample, it is intriguing that none of the 266
members of the ST-213 complex that were deposited at the time
of writing predated 1999. These data are not conclusive, but the
increase in the invasive serogroup B ST-213 meningococci
may have been related to the vaccine introduction, although
the increase in incidence may also have been due to the natural
meningococcal population change: this increase was in the
context of a decrease in meningococcal disease rates in the
UK [46]. This example highlights the importance of ongoing
surveillance of both carried and disease-causing meningococci
in the absence of comprehensive vaccines.
Irrespective of their likelihood to cause invasive disease, me-
ningococcal clonal complexes are characterized by particular
antigenic repertoires that persist for decades and during geo-
graphic spread [48]. The reasons for this remain a matter of
debate, but neither neutral nor micro-epidemic evolutionary
processes can account for the structuring observed [49], whereas
models that incorporate selection for fitness during transmission
can explain these features of meningococcal populations [33]. In
the absence of universal meningococcal polysaccharide vaccines,
which are precluded by the reluctance to include the serogroup
B capsular antigen [50], these ideas have important implications
for vaccine design. The effect of the MCC vaccine in eliminating
ST-11 complex serogroup C meningococci illustrates the po-
tential of an approach that targets particular transmission
phenotypes. In principle, vaccines based on rationally assembled
cocktails of antigens, which are effective against carriage, could be
used to target those invasive clonal complexes that are typically
associated with serogroup B capsules [48]. The results of the
present study, however, demonstrate that mass vaccination
campaigns affect population structure in ways that are not readily
anticipatable in advance of the intervention. Consequently, such
strategies require long-term surveillance of types that are found
in carriage and their association with invasive disease.
Funding
This work was supported by the Wellcome Trust (062057).
Acknowledgments
The authors are grateful to the following organizations for providing
research funding: the Wellcome Trust (sampling in England and Wales);
the Chief Scientist Office of the Scottish Executive Health Department
(sampling in Scotland); and the Meningitis Trust (questionnaire). We
thank the following for their assistance with implementation of the study:
A. D. Carr, C. Lewis, D. Casey, K. T. Dunkin, C. Roberts, R. A. Barnes,
J. Murray, A. Paull, Y. K. Lau (deceased), S. Welch, P. Marks, D. Turner,
D. Griffiths, M. Clacher, G. Lewendon, R. Mathews, and M. E. Ramsay.
We are indebted to the student volunteers and the many other individuals
who made this study possible, including nurses, laboratory staff, school
principals and staff, and colleagues who supported the study in various ways.
Martin Maiden is a Wellcome Trust Senior Fellow in Basic Biomedical
Sciences; and Derrick Crook is supported by the NIHR Biomedical Research
Centre, Oxford.
References
1. Makwana N, Riordan FA. Bacterial meningitis: the impact of vacci-
nation. CNS Drugs 2007; 21:355–66.
2. Trotter CL, McVernon J, Ramsay ME, et al. Optimising the use of
conjugate vaccines to prevent disease caused by Haemophilus influenzae
type b, Neisseria meningitidis and Streptococcus pneumoniae. Vaccine
2008; 26:4434–45.
3. Harrison LH, Trotter CL, Ramsay ME. Global epidemiology of me-
ningococcal disease. Vaccine 2009; 27:B51–63.
4. Campbell H, Borrow R, Salisbury D, Miller E. Meningococcal C con-
jugate vaccine: the experience in England and Wales. Vaccine 2009;
27:B20–9.
5. Pace D, Pollard AJ, Messonier NE. Quadrivalent meningococcal con-
jugate vaccines. Vaccine 2009; 27:B30–41.
6. Okoko BJ, Idoko OT, Adegbola RA. Prospects and challenges with
introduction of a mono-valent meningococcal conjugate vaccine in
Africa. Vaccine 2009; 27:2023–9.
7. Stephens DS. Biology and pathogenesis of the evolutionarily successful,
obligate human bacterium Neisseria meningitidis. Vaccine 2009;
27(suppl 2):B71–7.
8. Caugant DA, Maiden MC. Meningococcal carriage and diseased
population biology and evolution. Vaccine 2009; 27(suppl 2):B64–70.
9. Maiden MC, Ibarz-Pavon AB, Urwin R, et al. Impact of meningococcal
serogroup C conjugate vaccines on carriage and herd immunity.
J Infect Dis 2008; 197:737–43.
10. Maiden MC, Stuart JM, Group UMC. Carriage of serogroup C me-
ningococci 1 year after meningococcal C conjugate polysaccharide
vaccination. Lancet 2002; 359:1829–31.
11. Miller E, Salisbury D, Ramsay M. Planning, registration, and im-
plementation of an immunisation campaign against meningococcal
serogroup C disease in the UK: a success story. Vaccine 2001; 20:
S58–67.
1052 d JID 2011:204 (1 October) d Ibarz-Pavo´n et al
12. MacLennan J, Kafatos G, Neal K, et al. Social behavior and meningo-
coccal carriage in British teenagers. Emerg Infect Dis 2006; 12:950–7.
13. Auckland C, Gray S, Borrow R, et al. Clinical and immunologic risk
factors for meningococcal C conjugate vaccine failure in the United
Kingdom. J Infect Dis 2006; 194:1745–52.
14. Frosch M, Weisgerber C, Meyer TF. Molecular characterization and
expression in Escherichia coli of the gene complex encoding the poly-
saccharide capsule of Neisseria meningitidis group B. Proc Natl Acad Sci
U S A 1989; 86:1669–73.
15. Claus H, Maiden MC, Maag R, Frosch M, Vogel U. Many carried
meningococci lack the genes required for capsule synthesis and trans-
port. Microbiology 2002; 148:1813–9.
16. Claus H, Vogel U, Muhlenhoff M, Gerardy-Schahn R, Frosch M.
Molecular divergence of the sia locus in different serogroups of Neis-
seria meningitidis expressing polysialic acid capsules. Mol Gen Genet
1997; 257:28–34.
17. Swartley JS, Marfin AA, Edupuganti S, et al. Capsule switching of
Neisseria meningitidis. Proc Natl Acad Sci U S A 1997; 94:271–6.
18. Dolan-Livengood JM, Miller YK, Martin LE, Urwin R, Stephens DS.
Genetic basis for nongroupable Neisseria meningitidis. J Infect Dis
2003; 187:1616–28.
19. Maiden MC, Bygraves JA, Feil E, et al. Multilocus sequence typing:
a portable approach to the identification of clones within populations of
pathogenic microorganisms. Proc Natl Acad Sci U S A 1998; 95:3140–5.
20. Yazdankhah SP, Kriz P, Tzanakaki G, et al. Distribution of serogroups
and genotypes among disease-associated and carried isolates of Neis-
seria meningitidis from the Czech Republic, Greece, and Norway. J Clin
Microbiol 2004; 42:5146–53.
21. Maiden MC, Spratt BG. Meningococcal conjugate vaccines: new op-
portunities and new challenges. Lancet 1999; 354:615–6.
22. Cano R, Larrauri A, Mateo S, Alcala B, Salcedo C, Vazquez JA. Impact
of the meningococcal C conjugate vaccine in Spain: an epidemiological
and microbiological decision. Euro Surveill 2004; 9:11–5.
23. Vogel U, Claus H, Frosch M. Rapid serogroup switching in Neisseria
meningitidis. N Engl J Med 2000; 342:219–20.
24. Trotter CL, Maiden MC. Meningococcal vaccines and herd immunity:
lessons learned from serogroup C conjugate vaccination programs.
Expert Rev Vaccines 2009; 8:851–61.
25. Jolley KA, Maiden MC. BIGSdb: scalable analysis of bacterial genome
variation at the population level. BMC Bioinformatics 2010; 11:595.
26. Huson DH. SplitsTree: analyzing and visualizing evolutionary data.
Bioinformatics 1998; 14:68–73.
27. Feil EJ, Li BC, Aanensen DM, Hanage WP, Spratt BG. eBURST: in-
ferring patterns of evolutionary descent among clusters of related
bacterial genotypes from multilocus sequence typing data. J Bacteriol
2004; 186:1518–30.
28. Jolley KA, Chan MS, Maiden MC. mlstdbNetddistributed multi-locus
sequence typing (MLST) databases. BMC Bioinformatics 2004; 5:86.
29. Ortega-Sanchez IR, Meltzer MI, Shepard C, et al. Economics of an
adolescent meningococcal conjugate vaccination catch-up campaign in
the United States. Clin Infect Dis 2008; 46:1–13.
30. Dewhirst FE, Chen T, Izard J, et al. The human oral microbiome.
J Bacteriol 2010; 192:1422–31.
31. Holmes EC, Urwin R, Maiden MC. The influence of recombination
on the population structure and evolution of the human pathogen
Neisseria meningitidis. Mol Biol Evol 1999; 16:741–9.
32. Jolley KA, Kalmusova J, Feil EJ, et al. Carried meningococci in the
Czech Republic: a diverse recombining population. J Clin Microbiol
2000; 38:4492–8.
33. Buckee CO, Jolley K, Recker M, et al. Role of selection in the emergence
of lineages and the evolution of virulence in Neisseria meningitidis. Proc
Natl Acad Sci U S A 2008; 105:15082–7.
34. Claus H, Maiden MC, Wilson DJ, et al. Genetic analysis of meningo-
cocci carried by children and young adults. J Infect Dis 2005; 191:
1263–71.
35. Feavers IM, Gray SJ, Urwin R, et al. Multilocus sequence typing and
antigen gene sequencing in the investigation of a meningococcal dis-
ease outbreak. J Clin Microbiol 1999; 37:3883–7.
36. Gray SJ, Trotter CL, Ramsay ME, et al. Epidemiology of meningococcal
disease in England and Wales 1993/94 to 2003/04: contribution and
experiences of the Meningococcal Reference Unit. J Med Microbiol
2006; 55:887–96.
37. Russell JE, Urwin R, Gray SJ, Fox AJ, Feavers IM, Maiden MC.
Molecular epidemiology of meningococcal disease in England and
Wales 1975–1995, before the introduction of serogroup C conjugate
vaccines. Microbiology 2008; 154:1170–7.
38. Jones DM, Sutcliffe EM. Group A meningococcal disease in England
associated with the Haj. J Infect 1990; 21:21–5.
39. Jelfs J, Munro R, Ashto FE, Caugant DA. Genetic characterization of
a new variant within the ET-37 complex of Neisseria meningitidis as-
sociated with outbreaks in various parts of the world. Epidemiol Infect
2000; 125:285–98.
40. Vogel U, Claus H, Frosch M, Caugant DA. Molecular basis for dis-
tinction of the ET-15 clone within the ET-37 complex of Neisseria
meningitidis. J Clin Microbiol 2000; 38:941–2.
41. Castilla J, Vazquez JA, Salcedo C, et al. B:2a:P1.5 meningococcal strains
likely arisen from capsular switching event still spreading in Spain
10.1128/JCM.01495-08. J Clin Microbiol 2009; 47:463–5.
42. Taha MK, Achtman M, Alonso JM, et al. Serogroup W135 meningo-
coccal disease in Hajj pilgrims. Lancet 2000; 356:2159.
43. Bhattacharjee AK, Jennings HJ, Kenny CP. Structural elucidation of
3-deoxy-D-manno-octulosonic acid containing meningococcal 29-E
capsular polysaccharide antigen using C-13 nuclear magnetic-resonance.
Biochemistry 1978; 17:645–51.
44. Griffiss JM, Brandt BL. Immunological relationship between the
capsular polysaccharides of Neisseria meningitidis serogroups Z and 29E.
J Gen Microbiol 1983; 129:447–52.
45. Ala’Aldeen DA, Neil K, English A, Hawkey P. Isolation of a serogroup
29E meningococcal strain carrying Group-C siaD capsular gene.
J Infect 2002; 44:56–7.
46. Lucidarme J, Comanducci M, Findlow J, et al. Characterisation of
fHbp, nhba (gna2132), nadA, porA and sequence type in group B me-
ningococcal case isolates collected in England and Wales during
January 2008, and potential coverage of an investigational group B
meningococcal vaccine. Clin Vaccine Immunol 2010; 17:919–29.
47. Brehony C, Jolley KA, Maiden MC. Multilocus sequence typing for
global surveillance of meningococcal disease. FEMS Microbiol Rev
2007; 31:15–26.
48. Urwin R, Russell JE, Thompson EA, Holmes EC, Feavers IM, Maiden
MC. Distribution of surface protein variants among hyperinvasive
meningococci: implications for vaccine design. Infect Immun 2004; 72:
5955–62.
49. Jolley KA, Wilson DJ, Kriz P, McVean G, Maiden MC. The influence
of mutation, recombination, population history, and selection on
patterns of genetic diversity in Neisseria meningitidis. Mol Biol Evol
2005; 22:562–9.
50. Jodar L, Feavers IM, Salisbury D, Granoff DM. Development of vac-
cines against meningococcal disease. Lancet 2002; 359:1499–508.
Effects of Vaccination on Carried Meningococci d JID 2011:204 (1 October) d 1053
